Silvana Battaglia - 22 Jun 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Director
Signature
/s/ Steven Meetre, as Attorney-in-Fact
Issuer symbol
AGL
Transactions as of
22 Jun 2023
Net transactions value
$0
Form type
4
Filing time
26 Jun 2023, 17:26:58 UTC
Previous filing
13 Mar 2023
Next filing
10 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Award $0 +8,963 $0.000000 8,963 22 Jun 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Right to buy) Award $0 +19,251 $0.000000 19,251 22 Jun 2023 Common Stock 19,251 $16.74 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This grant of restricted stock units under the agilon health, inc. 2021 Omnibus Equity Incentive Plan (the "Plan") will vest in full on June 22, 2024, subject to the reporting person's continued service as a director.
F2 Includes restricted stock units.
F3 This option grant under the Plan will become exercisable in three equal installments on each anniversary of the grant date, commencing on June 22, 2024, subject to the reporting person's continued service as a director.